Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GBIO
stocks logo

GBIO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
650.00K
-84.48%
-3.537
+10.52%
0.00
-100%
-1.300
-40.91%
0.00
-100%
-1.243
-60.15%
Estimates Revision
The market is revising Upward the revenue expectations for Generation Bio Co. (GBIO) for FY2025, with the revenue forecasts being adjusted by 13.45% over the past three months. During the same period, the stock price has changed by -12.85%.
Revenue Estimates for FY2025
Revise Upward
up Image
+13.45%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+16.38%
In Past 3 Month
Stock Price
Go Down
down Image
-12.85%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Generation Bio Co (GBIO.O) is -0.72, compared to its 5-year average forward P/E of -4.13. For a more detailed relative valuation and DCF analysis to assess Generation Bio Co 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.13
Current PE
-0.72
Overvalued PE
0.74
Undervalued PE
-9.01

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.90
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.62
Undervalued EV/EBITDA
-4.42

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
99.02
Current PS
0.00
Overvalued PS
257.30
Undervalued PS
-59.25
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 223.76% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

GBIO News & Events

Events Timeline

(ET)
2025-10-22
16:50:34
Generation Bio CEO McDonough Resigns; Howze Appointed Interim CEO
select
2025-07-18 (ET)
2025-07-18
08:36:08
Generation Bio announces 1-for-10 reverse stock split
select
2025-01-06 (ET)
2025-01-06
15:52:24
Generation Bio chief scientific officer Matthew Stanton to leave role
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
10-29Newsfilter
Compass Pathways Names Dr. Jeffrey Jonas to Its Board of Directors

  • New Board Appointment: Compass Pathways has appointed Dr. Jeffrey Jonas to its Board of Directors, bringing over 30 years of experience in pharmaceutical research and neuroscience, effective immediately.

  • Retirement Announcement: Thomas Lönngren will retire from the Board at the end of December after more than six years of service, during which he contributed to the company's transition from early-stage to late-stage clinical development.

  • COMP360 Program Focus: The company is advancing its investigational COMP360 synthetic psilocybin treatment for treatment-resistant depression, which has received Breakthrough Therapy designation from the FDA.

  • Commitment to Mental Health Innovation: Dr. Jonas expressed enthusiasm for supporting Compass Pathways in transforming mental health care through innovative treatments, emphasizing the urgent need for effective solutions in the growing mental health crisis.

[object Object]
Preview
4.0
08-14Benzinga
Needham Reiterates Buy on Generation Bio, Maintains $15 Price Target

  • Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.

  • Exclusive Community Access: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.

[object Object]
Preview
8.5
08-13Benzinga
Why Sapiens International Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket

  • Sapiens International Acquisition: Sapiens International Corporation NV shares surged 43.7% in pre-market trading after announcing its acquisition by Advent, a private equity firm, in an all-cash deal valued at approximately $2.5 billion.

  • Market Movements: Several stocks experienced significant changes in pre-market trading, with notable gainers including Bolt Projects Holdings Inc (up 61.5%) and 180 Life Sciences Corp (up 51%), while losers included Profrac Holding Corp (down 29.4%) and CAVA Group Inc (down 24%).

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Generation Bio Co (GBIO) stock price today?

The current price of GBIO is 5.22 USD — it has decreased -0.19 % in the last trading day.

arrow icon

What is Generation Bio Co (GBIO)'s business?

Generation Bio Co. is a biotechnology company. The Company is engaged in developing redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells, which erroneously recognize and attack the body’s own tissues, causing autoimmune diseases. It focuses on autoimmune targets that have been undruggable or poorly drugged selectively in T cells. Its proprietary cell-targeted lipid nanoparticle (ctLNP) technology enables selective access to T cells and precise target inhibition by siRNA to selectively modulate T cells, blocking autoimmune tissue damage while sparing the broader immune system. Its proprietary stealth technology prevents its LNP from interacting with serum-binding proteins and reduces clearance by the liver and spleen to less than 1%, enabling potency and selectivity. Its selective delivery allows it to inhibit targets in T cells while sparing critical function in other cell types.

arrow icon

What is the price predicton of GBIO Stock?

Wall Street analysts forecast GBIO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GBIO is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Generation Bio Co (GBIO)'s revenue for the last quarter?

Generation Bio Co revenue for the last quarter amounts to 1.59M USD, decreased -78.90 % YoY.

arrow icon

What is Generation Bio Co (GBIO)'s earnings per share (EPS) for the last quarter?

Generation Bio Co. EPS for the last quarter amounts to -0.82 USD, decreased -64.19 % YoY.

arrow icon

What changes have occurred in the market's expectations for Generation Bio Co (GBIO)'s fundamentals?

The market is revising Upward the revenue expectations for Generation Bio Co. (GBIO) for FY2025, with the revenue forecasts being adjusted by 13.45% over the past three months. During the same period, the stock price has changed by -12.85%.
arrow icon

How many employees does Generation Bio Co (GBIO). have?

Generation Bio Co (GBIO) has 115 emplpoyees as of December 05 2025.

arrow icon

What is Generation Bio Co (GBIO) market cap?

Today GBIO has the market capitalization of 35.17M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free